One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...
New answer by Radiation Oncologist at University of California at Davis (August 16, 2021)
I do not routinely hold immunotherapy with lung SBRT. There is a substantial body of literature that suggests thoracic radiation is safe in tandem with immunotherapy, includin...